Nathan D. Trinklein, Ph.D.
Nathan is a co-founder and currently serves as the CEO of SwitchGear Genomics. As CEO, he manages SwitchGear's business development efforts and is in charge of identfying and building strategic partnerships and collaborations. Nathan also manages technology development, bioinformatics, and applications in the area of regulatory network/pathway analysis. Previous to founding SwitchGear, he managed the Stanford ENCODE Project and has over 8 years of experience and publications in the field of functional genomics. He received his Ph.D. from the Genetics Department at Stanford University.Shelley Force Aldred, Ph.D.
Shelley is a co-founder and currently serves as the President and COO of SwitchGear Genomics. As president, she manages the corporate structure, company finances, and investor relations. As COO, she directs all lab operations, inventory management, and product delivery. Shelley also oversees large collaborations and applications in the area regulatory element sequence variation and human genetics. She has over 8 years of experience and publications in the field of large-scale regulatory element analysis and the effects of promoter variants in human disease. She received her Ph.D. from the Genetics Dept at Stanford as a Geraldine Jackson Fuhrman Graduate Fellow.Brian McKelligon
Brian currently serves as the Vice President of Sales and Marketing at SwitchGear. He has over 15 years of industry experience most recently as the Director of North America Industrial Sales for Affymetrix. Prior to Affymetrix, Brian directed sales efforts at Ingenuity Systems, was Vice President of Business Development at Apollo Biotechnology and was a Director of Business Development at Incyte Pharmaceuticals. He received his B.S. in Biology and Chemistry from Santa Clara University.
BOARD OF DIRECTORS
Jim Hudson
Jim played an integral role in the Human Genome Project and is a well-respected member of the Genomics community. He is the founder and president of Research Genetics, a genomics reagent company in Huntsville, Alabama, that was acquired by Invitrogen in 1999 for $140M. He is also a founding board member of Shearwater Polymers and New Century Pharmaceuticals. Jim has recently co-founded the Hudson-Alpha Institute for Biotechnology, a large medical research institute in Huntsville, Alabama.Andrew Farquharson
Andrew Farquharson is an early-stage investor in life sciences, who brings 14 years of experience as a founder, executive and researcher in the biotherapeutic, genomic and proteomic arenas. He is a Kauffman Fellow and Chairman of Ergodesigns, Inc., which he founded in 2003. Mr. Farquharson served as Senior Vice President of sales and marketing for QIAGEN Operon, where he tripled revenues of synthetic DNA products in two years, and played a key role in negotiating a sale of the business for nine figures. Mr. Farquharson received a BA with High Honors from the University of California at Berkeley, and his Masters of Business Administration from Harvard University Graduate School of Business.Deval Lashkari
Deval has worked in the life sciences area over the past 18 years developing and commercializing novel technologies. He gained corporate and business development experience through senior management positions in a number of biotechnology companies. In addition, he was a founding Research Director at Synteni, which was acquired by Incyte Genomics, where he was Director of Product Development. He also worked with Operon Technologies, acquired by Qiagen, and Genometrix. He is currently a director of AcroMetrix, Althea Technologies, Applied Precision and Aurora Discovery. Deval received a BA from the University of California, Berkeley and a Ph.D. from Stanford University.Nathan D. Trinklein
Shelley Force Aldred
SCIENTIFIC ADVISORY BOARD
Richard M. Myers, Ph.D.
Rick is a co-founder of SwitchGear Genomics and currently serves as the chairman of the SAB. He has been an established leader for 25 years in the field of gene regulation of the genetics of human disease. Rick is currently the Chairman of the Genetics Department at Stanford University. He is also the Director of the Stanford Human Genome Center, a member of the the Advisory Council of the National Human Genome Research Institute, and an Associate Editor of Genome Research.James M. Ford, M.D.
Jim currently serves as a member of the SAB of SwitchGear Genomics. He is currently a professor at Stanford University in the Departments of Genetics and Medical Oncology. Jim is an established leader in the field of DNA damage, cancer, and translational medicine. He discovered that the p53 and BRCA1 tumor suppressor genes regulate DNA repair, and has developed novel assays to examine DNA repair activity in primary human tissues. He is developing techniques for high-throughput genomic analyses of cancer to identify molecular signatures for targeted therapies.